For the quarter ending 2025-09-30, OGEN had $9,430,021 increase in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -3,066,589 | -4,489,028 |
| Amortization of debt discount and closing costs | 0 | 771,437 |
| Stock-based compensation expense | 6,040 | 24,485 |
| Stock-based compensation recapture expense | 0 | -86,617 |
| Prepaid expenses and other current assets | 1,135,815 | -441,707 |
| Change in operating lease liabilities | - | 0 |
| Operating lease right of use assets | - | 0 |
| Accounts payable and accrued expenses | 1,211,849 | -88,444 |
| Net cash used in operating activities | -2,984,515 | -3,426,460 |
| Borrowings on short-term notes payable | 394,836 | 2,228,563 |
| Payments on short-term notes payable | 3,000,000 | 328,528 |
| Net proceeds from issuance of preferred stock and warrants | 15,019,700 | - |
| Net proceeds from issuance of common stock | 0 | 2,635,330 |
| Net cash provided by financing activities | 12,414,536 | 4,535,365 |
| Net decrease in cash and cash equivalents | 9,430,021 | 1,108,905 |
| Cash and cash equivalents at beginning of period | 864,840 | - |
| Cash and cash equivalents at end of period | 11,403,766 | - |
ORAGENICS INC (OGEN)
ORAGENICS INC (OGEN)